On a second alternative, I heard somebody from England speak a couple of months ago. They have the same concern we have about the gap between what you find from research and moving it along to a treatment that's accessible to patients. What they may be doing in the U.K. is a different approach, where the government is sort of walking in as a matchmaker between the universities and the biotech companies.
I can't give you an answer on dollars for that, but I can give you an idea that the government is prepared to play the role of bringing together the researchers and the drug companies. But I really can't give you a dollar figure for what that involvement would cost.